Italy· 043208038
XIGDUO*56 cpr rivestite 5 mg + 850 mg
A medicinal product containing dapagliflozin/metformina, registered in Italy by ASTRAZENECA AB, on the national reimbursement list.
Checked against the register on
Informational only — not a medical device.
The record
At a glance
- Active substance
- Dapagliflozin/Metformina
- Manufacturer
- ASTRAZENECA AB
- Country
- Italy (IT)
- ATC code
- —
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic043208038XIGDUO*56 cpr rivestite 5 mg + 850 mgEUR 56.1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c911e591-8de8-474a-aa5c-1e4ec2d5cc7f GET /v1/drugs/c911e591-8de8-474a-aa5c-1e4ec2d5cc7f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 56.1,
"source": "aifa",
"currency": "EUR",
"strength": "DAPAGLIFLOZIN+METFORMINA 5+850MG 56 UNITA' USO ORALE",
"substance": "Dapagliflozin/Metformina",
"equivalence_group": "EZD",
"transparency_flag": null
}See everything about dapagliflozin/metformina.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.